Insiders who have reported open-market trades at the same companies as BVF PARTNERS L P. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
BVF PARTNERS L P is an investment firm, tracked as Director of IMMUNIC, INC. (IMUX). InsiderAlpha holds 23 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has BVF PARTNERS L P submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has BVF PARTNERS L P been buying or selling stock?
Recorded transactions: 6 open-market purchases ($31.30M) and 18 open-market sales ($361.57M) across all tracked filings.
BVF PARTNERS L P is Director of IMMUNIC, INC. (IMUX). 23 SEC Form 4 filings on record going back to 2024, most recently on 18 September 2026. Most recent open-market trade: sold $5.52M of KYMR on 26 June 2026. Lifetime open-market purchases: $31.30M. Lifetime open-market sales: $361.57M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by BVF PARTNERS L P.
InsiderAlpha's records for BVF PARTNERS L P go back to 2024: 23 primary Form 4 filings, an average of 7.7 per year. The typical open-market purchase is $5.22M (6 buys totaling $31.30M). The largest single buy on record is $8.08M of ELDN in 2024. Sales side: 18 recorded sales totaling $361.57M, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
